GSK · Pharma and healthcare · one day
GSK (GSK): news on Friday 23 October 2026
News from the 24 hours to Friday morning, 23 October 2026.
Tone of the day
+7.2strongly positive
+7.2
Relevant headlines18
Stories8
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage focused on US approval of GSK's first-in-class hepatitis B drug Hibsago, alongside a positive Jemperli approval, strong lung cancer trial data and a higher share price. Gains were tempered by a reported profit fall, valuation caveats and a 40% malaria vaccine price cut.
What drove it
- Hibsago hepatitis B approval
- pipeline and trial data
- share price gains
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Sat 17 Oct | +2.0 | 10 |
| Sun 18 Oct | +0.7 | 2 |
| Mon 19 Oct | +8.5 | 7 |
| Tue 20 Oct | +8.3 | 37 |
| Wed 21 Oct | +10.0 | 26 |
| Thu 22 Oct | +10.0 | 37 |
| Fri 23 Oct | +7.2 | 18 |
| Sat 24 Oct | +8.0 | 15 |
| Sun 25 Oct | +2.0 | 6 |
| Mon 26 Oct | +5.7 | 5 |
8 stories · 18 headlines · strongest first
Pharma and healthcare on 23 OctoberFTSE 100 that day| Tone | Headline and why it scored that way | |
|---|---|---|
| FDA approves GSK's Hibsago for chronic hepatitis B +10.09 headlines today · 45 in all, since 21 October · Outlets report the US approval of GSK's hepatitis B drug Hibsago and its investment implications. | ||
| +10.0 | Hepatitis B Drug Approval Could Be A Game Changer For GSK (LSE:GSK)Hepatitis B approval described as potential game changer. | |
| +9.2 | How First In Class Hepatitis B Approval At GSK (LSE:GSK) Has Changed Its Investment StoryFirst-in-class hepatitis B approval improves investment story. | |
| +8.3 | GSK, Ionis hepatitis B functional cure breaks open market for followersFunctional cure opens market, positive for GSK and Ionis. | |
| +8.3 | Recon: FDA approves GSK hepatitis B drug; EQT to buy molecular testing firm Qiagen for $10.8BFDA approves GSK hepatitis B drug. | |
| +7.5 | GSK (LSE:GSK) Hibsago Approval Puts Discounted Earnings Valuation in FocusHibsago approval is a positive product milestone, valuation discussed. | |
| +7.5 | Why Is GSK (LSE:GSK) Stock Drawing Attention Today After A US Hepatitis B Approval?Stock attention following US hepatitis B approval. | |
| +7.5 | GSK wins Hibsago approval: Jefferies keeps GBp 2,500 target for GSK stockJefferies keeps GBp 2,500 target after approval. | |
| +3.3 | GSK (LSE:GSK) Stock May Trade At A Discount Despite Hibsago ApprovalApproval positive but stock may still trade at discount. | |
| +1.7 | Friday Five – On the eve of ESMO, GSK's cure comes with a catch, AbbVie's win-win week…and moreIndustry roundup noting GSK cure with a catch. | |
| GSK share price and valuation commentary +3.23 headlines today · 27 in all, since 16 October · Headlines report GSK shares up 1.6–2.5% and why they rose despite lower profit. | ||
| +5.0 | Why is GSK stock up 1.6% today?Share price up 1.6% on the day. | |
| +4.2 | GSK Testing Key Resistance: Stock Gains 2.46% (October 22, 2026)Share price gain of 2.46% testing resistance. | |
| +3.3 | Why GSK Rose Even Though Profit FellShares rose despite a fall in profit. | |
| GSK Ris-Rez shows 61% response rate in lung cancer trial +7.51 headline today · 15 in all, since 19 October · Indian Pharma Post reports a 61% response rate in an aggressive lung cancer trial. | ||
| +8.3 | GSK’s cancer drug shows 61% response rate in global trial for aggressive lung cancerStrong 61% response rate in aggressive lung cancer trial. | |
| FDA approves GSK's Jemperli for rectal cancer +9.61 headline today · 20 in all, since 20 October · Traders Union reports US approval for Jemperli and a positive R&D update. | ||
| +8.3 | GSK plc receives US approval for Jemperli and reports positive R&D update: Can GSK regain momentum?US approval for Jemperli and positive R&D update. | |
| GSK to invest over $800m in Pennsylvania +7.81 headline today · 23 in all, since 10 October · Plant Services reports GSK plans a biopharmaceutical manufacturing facility in Pennsylvania. | ||
| +6.7 | GSK plans to open biopharmaceutical manufacturing facility in PennsylvaniaPlans new Pennsylvania manufacturing facility, investment in capacity. | |
| TB vaccine from GSK and Gates Foundation targeted for 2029 +5.01 headline today · Kompas reports a minister's target for the TB vaccine to be produced by 2029. | ||
| +5.0 | Health Minister's Target: TB Vaccine from GSK and Gates Foundation to be Produced by 2029TB vaccine production target supports GSK vaccine programme. | |
| HUTCHMED licensing deal with GSK closes +5.81 headline today · 12 in all, since 15 October · Yahoo Finance reports HUTCHMED closed its GSK deal. | ||
| +3.3 | HUTCHMED (China) (AIM:HCM) Closes GSK Deal, Is The Stock Still 38% Undervalued?Hutchmed closes deal with GSK; GSK a named party. | |
| UNICEF and Gavi cut Mosquirix price by 40% −1.71 headline today · SRN News reports UNICEF and Gavi agreed a 40% price cut for the malaria vaccine. | ||
| −1.7 | UNICEF and Gavi agree to cut Mosquirix malaria vaccine price by 40%Malaria vaccine price cut by 40% reduces revenue per dose. | |
Each headline has its own score; the links go to the publisher.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.